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298the international CVD community, under the
umbrella of the World Heart Federation, joined
the NCD community to call for a United Nations
(UN) High-level Meeting on Non-communicable
Diseases, held in September 2011. At this meeting,
heads of state signed a Political Declaration that
committed governments to the development of 4
speciﬁc measures to address the NCD burden in
a speciﬁc timeline: (1) Recommendations for a global
monitoring framework that included NCD targets
to be completed by the end of 2012; (2) develop-
ment of a plan for an effective multisector partner-
ship by the end of 2012; (3) national NCD plans
by 2013; and (4) a comprehensive review to evaluate
progress, to take place in 2014 [2].
C E L E B RA T I NG TH E 2 0 2 5 G LOBA L NCD
MORTA L I T Y T A RG E T
Celebrating the 1-year anniversary of the passage of
the UN Political Declaration, it is timely that our
respective organizations speak with a single voice
to advocate for a set of public health interventions
that have the potential to mitigate and reverse the
rising rates of CVD and NCDs. In May 2012,
during the World Health Assembly, Ministers of
Health took the ﬁrst critical step by agreeing to
adopt a global target to reduce premature NCD
mortality 25% by 2025, a target the global CVD
community has been advocating since the UN
High-level Meeting on Non-communicable
Diseases [3]. We applaud the World Health
Assembly for reaching a consensus on this bold
goal.
The UN Political Declaration on NCDs and the
recent resolution to reduce premature NCD deaths
by 25% are landmark achievements for the health
and CVD community. For the ﬁrst time in history,
NCDs have been recognized as a development
issue. These targets and indicators have the poten-
tial to address longstanding health challenges,
including the fragmentation of health funding,
gaps in the healthcare infrastructure, and the lack
of local and reliable data, and will address the
growing demand for integrated disease manage-
ment. As the Millennium Development Goals
come to a close in 2015, the CVD community is
set to ensure that the single largest cause of deathe
CVDeis addressed. As such, all relevant stake-
holders need to be part of the process, putting
optimal health at the cornerstone of development.
It is our desire to see heart disease and stroke
receive the attention they deserve. We recognizethat the process is complex and the time is short,
but we have an opportunity to ensure that the
commitments made in September 2011 translate
into real global, and thus national, action for years
to come. Collaboration among appropriate stake-
holders will be necessary to address this emerging
21st century global health priority and begin to
reverse the devastating toll of CVD and NCDs in
our communities.
MA IN TA I N I NG TH E MOMENTUM TO
ADDR E S S O TH E R TARG E T S
A ﬁrst step toward global action has been the
passage of the global mortality target, which will
provide a shared vision on NCDs for all stake-
holders and ensure that all targets are appropriately
developed to achieve this overarching goal. As the
leading organizations that represent thousands of
members in nearly every country, and for the
millions of individuals with, or at risk of CVD,
we are aligning with the broader NCD community
in support of a comprehensive set of additional
targets that will ensure this global reduction is
achieved.
The challenge faced by countries will be to reach
agreement concerning the additional targets and
indicators to be part of the comprehensive moni-
toring framework to achieve the overarching global
mortality target. In the summer of 2010, a World
Health Organization (WHO) technical working
group developed 10 proposed global targets
(Appendix A), which remained virtually
unchanged until the spring of 2012 [4]. At that
time, Member States, civil society organizations,
and other relevant stakeholders were asked to
comment on and make speciﬁc recommendations
regarding the global monitoring framework for
NCDs and the speciﬁc targets and indicators that
would be used to guide countries and measure
progress. The original set of 10 targets was reduced
before completion of regional consultations and
with limited input of Member States (Appendix
B) [5]. Calls to action from the CVD, NCD,
and speciﬁc risk-factor communities did, however,
lead to positive changes within this reduced set of
targets and included the insertion of a new target
on physical activity. The inclusion of this target
in the list of recommendations was a milestone in
NCD advocacy efforts, ensuring that each of the
major risk factors leading to NCDs was addressed.
With the release of the third WHO discussion
paper [6], the NCD community’s advocacy efforts
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299are to be noted as the list of recommended targets
for adoption includes 10 strong, evidence-based
strategies. Together, the Global Cardiovascular
Disease Taskforce calls on the CVD community
to endorse and support the top 4 widely supported
exposure targets (Table 1) on physical inactivity,
hypertension/blood pressure, dietary salt intake,
and tobacco as those required to achieve the over-
arching goal of a 25% reduction in premature
mortality by 2025.
Other, originally proposed targets to address
NCDs that were dropped in the second WHO
discussion paper include evidence-based targets on
obesity, trans fat/fat intake, alcohol, and multidrug
therapy to prevent and treat CVD (Table 2) [7].
Although these targets have been included in the
most recent discussion paper, they have been iden-
tiﬁed as having limited support and will need
further advocacy to ensure their adoption [7]. In
addition to supporting the NCD community in
their call for Member States to agree on this global
set of 10 voluntary targets, we also explicitly call for
Member States to be ambitious and ensure that they
address those persons at highest risk now by adopt-
ing the additional exposure and health systems
targets currently under consideration.
To halt and reverse the NCD epidemic, it is
paramount that the CVD burden be adequately
addressed, which requires that those living with
CVD and at highest risk of developing CVD have
access to treatment and care. The 2011 report by
the WHO, Scaling Up Action Against Noncommuni-
cable Diseases: How Much Will It Cost?, details a core
set of low-cost strategies, identiﬁed as “Best Buys”
that all countries can implement to prevent and treat
NCDs. This list includes population-based
measures to address risk factors and speciﬁc indi-
vidual-based interventions, including a multidrug
therapy regimen of aspirin, a statin, and blood pres-
sure-lowering agents to prevent heart disease andTable 1. Suggested Global Targets to Address NCDs With Wide Su
Proposed Target
1 Physical inactivity: 10% Relative reduction in prevalence of insufﬁcie
2 Raised blood pressure: 25% Relative reduction in prevalence of raise
3 Salt/sodium intake: 30% Relative reduction in mean population intake
recommended level of <5 g/d (2000 mg of sodium)
4 Tobacco: 30% Relative reduction in prevalence of current tobacco sm
NCDs indicate noncommunicable diseases.stroke and to treat those with, or at highest risk
of, heart disease and stroke [8]. As Member States
determine how best to achieve this global target,
the global CVD community looks to this package
of the WHO’s “Best Buys” as a critical way forward.
CVD AND THE WHO B E S T BUY S
With CVD as the largest single contributor to
global mortality, accounting for nearly half of the
36 million NCD deaths, and with a global cost of
nearly US $863 billion, achieving the global target
to reduce premature NCD deaths by 25% requires
that CVD and its risk factors be adequately
addressed [9]. The Global Cardiovascular Taskforce
supports the set of recommendations identiﬁed by
the WHO as “Best Buys,” feasible and cost-effective
interventions that can be undertaken regardless of
the income level of a country. This core set of inter-
ventions are recommended at 2 levelsepopulation-
wide measures to reduce exposure to risk factors
and interventions targeting individuals who already
have NCDs or are at high risk of developing
themeand are implemented through a systematic
layered approach. Regarding population-wide risk
factor measures, the WHO has identiﬁed “Best
Buys” in the areas of tobacco use, harmful use of
alcohol, salt intake, physical activity, and replace-
ment of trans fat with polyunsaturated fat. Interven-
tions targeting individuals include evidence-based,
cost-effective medical therapies alongside coun-
seling, as well as aspirin therapy for acute myocardial
infarction [10].
On the occasion of the UN High-level Meeting
in September 2011, the WHO introduced a tool for
low-, middle-, and high-income countries to guide
and estimate the feasibility of the implementation
of this core set of NCD interventions [8]. The
cost of the interventions is <US$11.4 billion per
year in low- and middle-income settings. Yearly,pport (See Appendix C)
Best
Buy
Recommendation to
Member States
nt physical activity U Adopt
d blood pressure U Adopt
of salt, with aim of achieving U Adopt
oking U Adopt
Table 2. Proposed Targets and Indicators to Address NCDs With Some Support (See Appendix C)
Proposed Target
Best
Buy
Recommendation to
Member States
5 Saturated fat intake: 15% Relative reduction in mean proportion of total energy intake from
saturated fatty acids (SFA), with aim of achieving a recommended level of <10% of total energy
intake
U Adopt with modiﬁcation
6 Obesity: Halt the rise in obesity prevalence Adopt
7 Alcohol: 10% Relative reduction in overall alcohol consumption (especially hazardous, excessive, and
harmful drinking)
U Adopt with modiﬁcation
8 Raised cholesterol: 20% Relative reduction in prevalence of raised total cholesterol Adopt
9 Drug therapy to prevent heart attacks and strokes: 50% Of eligible people receive drug therapy to
prevent heart attacks and strokes, and counseling
U Adopt
10 Essential NCD medicines and basic technologies to treat major NCDs: 80% Availability of basic
technologies and generic essential medicines required to treat major NCDs in both public and
private facilities
Adopt
NCDs indicate noncommunicable diseases.
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300per person, this translates to <US$1 a day
(US$0.43-US$0.90) across low-income countries
and <US$3 a day (US$0.54-US$2.93) across
middle-income countries [11].
Several of the 10 targets being supported by the
NCD community have been identiﬁed within this
core set of “Best Buy” interventions and are at risk
of failing to be adopted as global targets, including
the evidence-based drug therapy regimen to address
those at highest risk for developing CVD. Studies
have indicated that nearly 17.9 million deaths could
be averted over a 10-year period with the implemen-
tation of multidrug therapy [11]. The cost would
amount to just over US$1 a day annually. Beyond
the lives saved and the life-years extended, reducing
the mortality rate for ischemic heart disease and
stroke by 10% would also reduce economic losses
in low- and middle-income countries by an esti-
mated US$25 billion per year [12]. Drug therapy,
singly or in combination with multiple drugs, is
documented to be a concrete investment and should
be a target to be accomplished.
As Member States look to ﬁnalize targets in the
coming months, doubt regarding country-level
compliance in the implementation of NCD inter-
ventions, as a result of underdeveloped monitoring
and surveillance systems, must not overshadow the
real, cost-effective, and feasible solutions offered
by the WHO “Best Buys.” Collection of data, for
all targets, remains a critical issue that can, and
should, be addressed through the Global Moni-
toring Framework. It is recognized that target levelsmay vary slightly in different regions of the world.
As such, when considering national NCD action
plans, all targets will require adequate and well-
developed indicators that encourage the improve-
ment of data at the country level and provide an
impetus to countries that have the tools to collect
and monitor data. Moreover, improved healthcare
delivery and an expanded health workforce with
coordination of local and national approaches are
paramount in building comprehensive health
systems to achieve this end.GLOBA L CARD I OVA S CU LAR
TA S K FORC E SUMMARY PO S I T I ON :
P R E V EN T I ON , R I S K FA C TOR S , AND
T R EA TMENT
Member States have taken the ﬁrst step and set
a bold overarching goal of reducing mortality from
NCDs by 25% by 2025. We now have the opportu-
nity to make meaningful changes in our countries by
adopting evidence-based targets and implementing
tactics that will guide health policy, chronic disease
plans and, ultimately, resources for national public
health interventions. Many of these are feasible
and cost-effective. Reducing NCDs are central to
a country’s economic growth. As such, we respect-
fully request Member States to consider our recom-
mendations and adopt the evidence-based targets to
address CVD and NCDs and avert millions of
deaths by 2025.
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301AP P END I X A . O R I G I NA L S E T O F TA RG E T SOutcome Targets Indicator Source
Premature mortality from NCDs Unconditional probability of dying between
ages 30 and 70 y from CVD, cancer, dia-
betes, or chronic respiratory disease
Civil registration system, with medical
certiﬁcation of cause of death, or survey
with verbal autopsy
25% Relative reduction in overall
mortality from CVD, cancer, diabetes,
or chronic respiratory disease
Diabetes Age-standardized prevalence of diabetes
mellitus among persons age 25 y (deﬁned
as fasting plasma glucose 7.0 mmol/L
[126 mg/dL] or on treatment for diabetes)
National survey (with measurement)
10% Relative reduction in the prevalence
of diabetes mellitus (elevated blood
glucose level 7.0 mmol/L [26 mg/dL]
or on treatment for diabetes)
Exposure Targets
Tobacco smoking Age-standardized prevalence of current
tobacco smoking among persons age 15 y
National survey
40% Relative reduction in prevalence of
current tobacco smoking
Alcohol Per capita consumption of pure liters of
alcohol among persons age 15 y
Ofﬁcial statistics and reporting systems for
production, import, export, and sale or
taxation data and national survey
10% Relative reduction in alcohol per
capita consumption among persons
age 15 y
Dietary salt intake Age-standardized mean population intake
of salt per day in grams
National survey (with measurement)
Mean adult population intake of salt
<5 g/d (2000 mg of sodium)
Blood pressure/hypertension National survey (with measurement)
25% Relative reduction in the prevalence
of elevated blood pressure (deﬁned as
systolic blood pressure 140 mm Hg and/
or diastolic blood pressure 90 mm Hg)
Obesity Age-standardized prevalence of obesity
(deﬁned as BMI 30 kg/m2) in persons age
25 y
National survey (with measurement)
No increase in obesity prevalence
Prevention of heart attack and stroke Percentage of people age 30 y with a 10-y
risk of heart attack or stroke 30%, or
existing CVD who are currently on multi-
drug therapy (including glycemic control)
National survey (with measurement)
80% Coverage of multidrug therapy
(including glycemic control) for people
age 30 y with a 10-y risk of heart attack
or stroke 30%, or existing CVD
Cervical cancer screening Prevalence of women between ages 30 and
49 y screened for cervical cancer at least
once
National survey; health facility data
80% Of women between ages 30 and
49 y screened for cervical cancer at least
once
Elimination of industrially produced trans
fatty acids (PHVO) from the food supply
Adoption of national policies that eliminate
PHVOs in the food supply
Policy review
NCDs indicate noncommunicable diseases; CVD, cardiovascular disease; BMI, body mass index; and PHVO, partially hydrogenated vegetable oil.
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302A PP END I X B . R EDUC ED L I S T O F TA RG E T SOutcome Targets Indicator Data Source(s)
Mortality from NCDs Unconditional probability of dying
between ages 30 and 70 y from CVD,
cancer, diabetes, or chronic respiratory
disease
Civil registration system, with medical certiﬁ-
cation of cause of death, or survey with verbal
autopsy
25% Relative reduction in overall
mortality from CVD, cancer, diabetes,
or chronic respiratory disease
Blood pressure/hypertension 25% relative reduction in the prevalence
of elevated blood pressure (deﬁned as
systolic blood pressure 140 mm Hg and/or
diastolic blood pressure 90 mm Hg)
National survey (with measurement)
25% Relative reduction in the prevalence
of elevated blood pressure (deﬁned as
systolic blood pressure 140 mm Hg
and/or diastolic blood pressure
90 mm Hg)
Tobacco smoking Age-standardized prevalence of current
tobacco smoking among persons
age 15 y
National survey
40% Relative reduction in prevalence
of current tobacco smoking
Dietary salt intake Age-standardized mean population
intake of salt per day in grams
National survey (with measurement)
Mean adult population intake of
salt <5 g/d (2000 mg of sodium)
Physical inactivity Age-standardized prevalence of obesity
(deﬁned as BMI 30 kg/m2) in persons
age 25 y
National survey
10% Relative reduction in prevalence
of insufﬁcient physical activity in adults
aged 18 y
NCDs indicate noncommunicable diseases; CVD, cardiovascular disease; and BMI, body mass index.
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303AP P END I X C . C U R R EN T S E T O F TA RG E T SOutcome Targets Indicator Data Source(s)
Premature mortality from NCDs Unconditional probability of dying between
ages 30-70 y from CVD, cancer, diabetes, or
chronic respiratory disease
Civil registration system, with medical certiﬁ-
cation of cause of death, or survey with verbal
autopsy
25% Relative reduction in overall
mortality from CVD, cancer, diabetes,
or chronic respiratory disease
Exposure Targets
Alcohol Total (recorded and unrecorded) alcohol
per capita (15 y) consumption within
a calendar year in liters of pure alcohol
Ofﬁcial statistics and reporting systems for
production, import, export, and sales or taxa-
tion data
10% Relative reduction in overall alcohol
consumption (including hazardous and
harmful drinking)
Fat intake Age-standardized mean proportion of
total energy intake from saturated fatty
acids (SFA) in adults aged 18 y
National survey
15% Relative reduction in mean
proportion of total energy intake from
saturated fatty acids (SFA), with aim of
achieving recommended level of
<10% of total energy intake
Obesity Age-standardized prevalence of obesity
among adults aged 18 y
National survey (with measurement)
Halt the rise in obesity prevalence
Physical inactivity Age-standardized prevalence of insufﬁcient
physical activity in adults aged 18 y
National survey
10% Relative reduction in prevalence
of insufﬁcient physical activity
Raised blood pressure Age-standardized prevalence of raised
blood pressure among adults aged 18 y
National survey (with measurement)
25% Relative reduction in prevalence
of raised blood pressure
Raised cholesterol Age-standardized prevalence of raised total
cholesterol among adults aged 18 y
National survey (with measurement)
20% Relative reduction in prevalence
of raised total cholesterol
Salt/sodium intake Age-standardized mean adult (aged 18 y)
population intake of salt per day
National survey (with measurement)
30% Relative reduction in mean
population intake of salt, with aim
of achieving recommended level of
<5 g/d (2000 mg of sodium)
Tobacco Age-standardized prevalence of current
tobacco smoking among persons
aged 15 y
National survey
30% Relative reduction in prevalence
of current tobacco smoking
Health Systems Response Targets
Drug therapy to prevent heart attacks
and strokes
Drug therapy to prevent heart attacks and
strokes (including glycemic control), and
counseling for people aged 40 y with
a 10-year cardiovascular risk 30% (includes
those with existing cardiovascular disease)
National survey
50% Of eligible people receive drug
therapy to prevent heart attacks and
strokes, and counseling
Essential NCD medicines and basic
technologies to treat major NCDs
Availability of basic technologies and
generic essential medicines required to
treat major NCDs in public and private
sector facilities, including primary care
facilities
Facility data
80% Availability of basic technologies
and generic essential medicines required
to treat major NCDs in both public and
private facilities
NCDs indicate noncommunicable diseases; CVD, cardiovascular disease.
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